AB1870
Anti-Osteopontin Antibody
serum, Chemicon®
Synonym(s):
Uropontin, Bone sialoprotein 1, SPP1/CALPHA1 fusion, Urinary stone protein, bone sialoprotein I, osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein, secreted phosphoprotein 1, secreted phosphoprotein 1 (osteopontin, bone sialop
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
mouse, rat, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... SPP1(6696)
General description
Osteopontin is a single-chain polypeptide with a molecular weight of approximately 35 kDa. It is a glycoprotein first identified in osteoblasts. It is biosynthesized by a variety of tissue types including preosteoblasts, osteoblasts, osteocytes, extraosseous cells in the inner ear, brain, kidney, deciduum, placenta, odontoblasts, some bone marrow cells, hypertrophic chondrocytes, macrophages, smooth muscle, and endothelial cells. Osteopontin is overexpressed in a variety of cancers, including lung cancer, breast cancer, colorectal cancer, stomach cancer, ovarian cancer, melanoma and mesothelioma. It may contribute to kidney stone formation and both glomerulonephritis and tubulointerstitial nephritis and is also found in atheromatous plaques within arteries. Research has implicated osteopontin in excessive scar-forming and a gel has been developed to inhibit its effect.
Specificity
Expected to cross-react with rat.
Human osteopontin. Does not cross react with osteonectin or human bone sialoprotein II.
Immunogen
Synthetic peptide corresponding to amino acids 75-90 of human osteopontin (SwissProt Accession # P10451; PSKSNESHDHMDDM DD).
Application
Immunohistochemistry:
A previous lot of this antibodu was used at a 1:1500 dilution on paraffin-embedded tissue sections.
ELISA:
A previous lot of this antibody was used at a 1:1000 dilution.
Optimal working dilutions must be determined by end user.
A previous lot of this antibodu was used at a 1:1500 dilution on paraffin-embedded tissue sections.
ELISA:
A previous lot of this antibody was used at a 1:1000 dilution.
Optimal working dilutions must be determined by end user.
Research Category
Cell Structure
Cell Structure
Research Sub Category
Osteobiology
Osteobiology
This Anti-Osteopontin Antibody is validated for use in ELISA, IH, IH(P), WB for the detection of Osteopontin.
Quality
Routinely evaluated by Western Blot on RAW 264.7 lysates.
Western Blot Analysis: 1:500 dilution of this lot detected osteopontin on 10 μg of RAW 264.7 lysates.
Western Blot Analysis: 1:500 dilution of this lot detected osteopontin on 10 μg of RAW 264.7 lysates.
Target description
~35 kDa
Physical form
Rabbit polyclonal antiserum in buffer containing no preservatives.
Unpurified
Storage and Stability
Stable for 1 year at -20°C in undiluted aliquots from date of receipt.
Handling Recommendations:
Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations:
Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
POSITIVE CONTROL: Human urine (2-5 µg/mL normal concentration).
POSITIVE CONTROL: Human urine (2-5 µg/mL normal concentration).
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nazwin Basheer et al.
European endodontic journal, 6(3), 295-302 (2021-12-31)
The aim of this study was to comparatively evaluate the proliferation, differentiation and mineralization inducing potential of strontium incorporated tetracalcium phosphate cement (STTCP) and mineral trioxide aggregate (MTA) on human dental pulp stem cells (hDPSCs). hDPSCs were cultured from freshly
Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.
Matsue, Y; Tsutsumi, M; Hayashi, N; Saito, T; Tsuchishima, M; Toshikuni, N; Arisawa, T; George, J
Testing null
Mirjam Fröhlich et al.
Tissue engineering. Part A, 16(1), 179-189 (2009-08-15)
We report engineering of half-centimeter-sized bone constructs created in vitro using human adipose-derived stem cells (hASCs), decellularized bone scaffolds, and perfusion bioreactors. The hASCs are easily accessible, can be used in an autologous fashion, are rapidly expanded in culture, and
Sequential application of steady and pulsatile medium perfusion enhanced the formation of engineered bone.
Correia, C; Bhumiratana, S; Sousa, RA; Reis, RL; Vunjak-Novakovic, G
Tissue Engineering: Part A null
Warren L Grayson et al.
Tissue engineering. Part A, 14(11), 1809-1820 (2008-07-16)
We describe a novel bioreactor system for tissue engineering of bone that enables cultivation of up to six tissue constructs simultaneously, with direct perfusion and imaging capability. The bioreactor was used to investigate the relative effects of initial seeding density
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service